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Introduction 
Angioedema is characterized by an asymmetric 
nondependent swelling that is generally not pruritic. 
The pathogenesis of angioedema results from 
increased vascular permeability, with leakage of 
plasma  into the deeper skin layers in patients with 
angioedema.1,2 Hereditary angioedema (HAE) is a 
rare  genetic life-long disabling disease that 
predisposes an individual to develop vasogenic 
edema.3  HAE is an autosomal dominant disease, 
and most patients with HAE have a positive family 
history of angioedema.3 The prevalence of HAE is 
estimated to be between 1:30,000 and 1:80,000 in 
the general population, and there is no evidence of 
sex, ethnic, or racial differences in the prevalence of 
HAE. 1 Awareness and recognition of this disease is 
important as HAE is often misdiagnosed as allergic 
angioedema or acute abdomen (especially acute 
appendicitis). This may often lead to inappropriate 
use of antihistamines, corticosteroids, adrenaline 
and sometimes even surgical interventions.4 
 
Etiology and classification 
HAE has classically been recognized as resulting 
from a deficiency of the C1-inhibitor (C1-INH) 
which is a  broad-spectrum serine protease inhibitor 
and is further subdivided into type I or type II HAE, 
depending on whether the plasma C1-INH antigenic 
levels are low or normal, respectively.5,6 Type I 
HAE is the most common and accounts for more 
than 80 % of the cases. It presents with low C1-INH 
antigenic and functional levels, whereas type II 
HAE presents with normal C1-INH antigenic levels 
but decreased C1-INH functional levels. However, 
there are other rare types of HAE now genetically 
identified with normal level and function of C1-
INH but due to other genetic defects (HAE- nC1-
INH). Another form of HAE with unknown genetic 
mutation has been as well identified. 7  
 
Genetics 
C1-INH gene (now named SERPING1), is located 
on chromosome 11 (p11.2-q13), contains 8 exons 
and 7 introns, does not contain a 59 TATA box, and 
is distinguished by 17 Alu repeats in introns 3 to 7.8 
HAE is an autosomal dominant disease caused by 
mutations in the SERPING1 gene. Missense 
mutations constitute approximately 30-40% of all 
mutations in SERPING1 gene.9 Each child of an 
affected patient has a 50% chance of having HAE. 
Importantly, HAE does not skip generations. 
However, lack of a positive family history of 
angioedema cannot be used to exclude the diagnosis 
as 25% of patients presumably have a de novo 
mutation of the SERPING1 gene.10 Genetic defects 
are identified in the very rare type of HAE nC1-
INH including gain of function mutation of factor 
XII gene (HAE-FXII)11 which is transmitted as 
autosomal dominant, missense mutation in the 
plasminogen gene (HAE-PLG) resulting in 
increased production of the bradykinin through 
activation of factor XII12, and lastly the novel 
mutation discovered in angiopoietin 1 (ANGPT1) 
gene (HAE-ANGPTI), the mutant protein is unable 
to bind to its receptor on endothelial cells to 
maintain  vascular permeability.13 
 
Pathophysiology 
C1-INH is a member of the serpin (serine protease 
inhibitor) superfamily with significant homology to 
a1-antitrypsin.  It has important roles in inhibiting 
several complement proteases (C1r, C1s, and 
mannose-binding lectin–associated serine protease 
[MASP] 1 and 2) and contact-system proteases 
(plasma kallikrein and coagulation factor XIIa) as 
well as a relatively minor inhibitor of the 
fibrinolytic protease plasmin.5, 14 
The primary mediator of swelling in HAE-1/2 is 
bradykinin.  Bradykinin is a low molecular weight 
nonapeptide, which is generated when active 
plasma kallikrein cleaves high molecular weight 
kininogen (HMWK). Plasma kallikrein is activated 
from its inactive zymogen prekallikrein by the 
protease factor XII which can easily autoactivate 
upon contact with negatively charged surfaces. 
Kallikrein is capable of directly converting 
plasminogen to plasmin and also with the help of 
urokinase type plasminogen activator. Plasmin and 
kallikrein in turn augment Factor XIIa generation 
thereby creating an auto-activation loop. 




the body including normal homeostasis, normal 
immune responses, inflammation, vascular tone, 
and vascular permeability. The vascular 
permeability–increasing effect of bradykinin in 
angioedema is primarily mediated through the 
bradykinin B2 receptor. Both plasma kallikrein and 
factor XII are normally inhibited by C1-INH. 
Bradykinin is rapidly metabolized by endogenous 
metalloproteases including angiotensin-converting 
enzyme (ACE).15,16 On the other hand, the 
pathogenesis in patients with HAE-nC1-INH 
remains to be characterized. However, there is 
clinical evidence that bradykinin may play a major 
role in some types of HAE nC1-INH, primarily in 
patients with a F12 gene-mutation.17 
As HAE-nC1-INH usually presents in the 
adulthood and may have special characteristics in 
addition to some features of HAE-type I/II, this 




The symptoms may occur at any age but 
uncommon in neonates or during infancy. They 
usually begin in childhood or adolescence, the 
median age of symptom onset is approximately 12 
years of age and worsens around puberty.18 
However, reports of early onset HAE by the age of 
4 weeks19 and another in one-year infant20 have 
been documented. The earlier the onset of 
symptoms, the more severe the subsequent course 
of HAE-type I/II. 21  
HAE is characterized by relatively prolonged 
attacks of angioedema involving the extremities, 
abdomen, genitourinary tract, face, oropharynx, 
larynx, or a combination of these areas. skin 
involvement is the most frequent location of the 
edema (91% of patients) followed in frequency by 
abdominal attacks (73%) and upper airway edema 
(48%). Viewing per-episode, nearly all episodes 
consisted of skin swellings and abdominal attacks 
(96.5%) with rare laryngeal events  (0.9%), but 
potentially life threatening. The swelling in patients 
with HAE is always episodic and not continuous 
daily swelling. Typical HAE attack tends to 
progressively worsen for 24 hours and then slowly 
remit over the following 48 to 72 hours; however, 
attacks can occasionally last longer, particularly if 
the swelling moves from site to site.1,18 
Subcutaneous edema of the extremities is often 
the earliest and most common swelling site in 
pediatric 
patients. Bowel wall edema and related 
symptoms of colicky abdominal pain, nausea, 
vomiting, and postattack watery diarrhea are 
common (80–90%) in the pediatric patients.  Less 
severe abdominal symptoms may be an 
unrecognized and often overlooked symptom of 
HAE in infancy.18,22,23 Subcutaneous edema is the 
most common and the earliest symptom.  Asphyxia 
may ensue rapidly in children, probably because of 
smaller airway diameter.24   
Several stressors have been associated with 
precipitating HAE attacks, especially mechanical 
trauma, emotional stress, and airway infections. 20,22 
In adolescent girls, menstruation and ovulation are 
additional triggers.25 Other precipitating factors 
include exercises,  and iatrogenic trauma, such as 
dental work, medical procedures, and surgery. Also, 
ACE-Is can precipitate attacks of angioedema 
although uncommonly used in pediatric 
population.1,20  
Patients with HAE can experience prodromal 
manifestations several hours or up to a day before 
the onset of an attack. The most common prodromal 
symptoms are an erythematous nonurticarial rash 
(erythema marginatum), localized tingling, or a 
sense of skin tightness. Erythema marginatum as a 
prodromal sign is more frequent in the pediatric 
population. It has been observed in 42% to 58% of 
cases and is often mistaken for urticaria. 
Misdiagnosis of prodromal erythema marginatum 
can lead to incorrect or insufficient treatment.26-28 
Other prodromal symptoms include fatigue, 
malaise, flu-like symptoms, irritability, mood 
changes, hyperactivity, thirst, or nausea. However, 
these symptoms are less commonly reported by 
children.1 
Higher incidence of concomitant celiac disease 
has been observed in HAE-type I/II pediatric 
patients. Celiac dietary restriction may reduce 
abdominal symptoms in these patients.29 
  
Diagnosis 
HAE-type I/II should be suspected when a 
child/adolescent presents with a history of recurrent 
angioedema attacks without urticaria. This 
suspicion is further substantiated when there is a 
positive family history (although this may not be 
present in up to 25% of patients), recurrent and 
painful abdominal symptoms, occurrence of upper 
airway edema, failure to respond to antihistamines, 
glucocorticoids, or epinephrine, and presence of 
prodromal signs or symptoms before swellings.7 
Measuring complement C4 levels is 
recommended as the best initial screening test to 
exclude a diagnosis of HAE,30,31 but its sensitivity 
and specificity are limited.32,33 The next step should 
be to measure C1INH antigen (and function if the 
antigenic level is normal). The functional level 
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should be less than 50% to 60% of the lower limit 
of normal to be compatible with HAE. In a patient 
with a compatible history and clinical course, the 
combination of low C4 and low C1-INH antigen 
levels can confirm a diagnosis of type I HAE; the 
combination of low C4 levels, normal C1-INH 
antigen levels, and low C1-INH function can 
confirm a diagnosis of type II HAE.30,34 A 
chromogenic functional C1-INH assay appears to 
be superior to the ELISA-based C1-INH functional 
assay.35 
The measurement of C4, however, was found 
not to be useful for diagnosing of HAE-type I/II in 
infants below the age of 12 month, as C4 levels are 
frequently low in healthy infants36, 37, thus should be 
repeated after the age of 1 year.36-38 Abnormal 
results should be confirmed by repeating once to 
exclude ex vivo degradation of the sample or 
laboratory error. Complement C3 and CH50 levels 
are expected to be normal in HAE, and testing is 
usually not helpful.1 
Genetic testing is not required to confirm the 
diagnosis of C1-INH-HAE unless prenatal testing is 
considered or in rare cases where  biochemical tests 
are inconclusive  and genetic mutation of the 
parents is known. Taken into considerations  that 
not all of the mutations detected by routine genetic 
testing are undoubtedly disease causing.36-39  
It is important to establish the diagnosis as early 
as possible, ideally before the onset of clinical 
manifestations. Therefore, family members of 
HAE-type I/II patients should be screened for C1-
INH function, C1-INH protein, and C4 plasma 
levels. Delayed diagnosis leads to morbidity and 
decreased quality of life due to delayed introduction 
of appropriate therapy. There is a risk that the first 
HAE attack might affect the airway and could be 
fatal.1, 7, 38 
 
Differential diagnosis 
This include the other forms angioedema namely 
acquired angioedema due to C1-Inhibitor deficiency 
(AAE-C1-INH ),  angiotensin converting enzyme 
inhibitor-induced angioedema (ACEI-AE), mast 
cell-mediated angioedema (e.g. angioedema in 
patients with chronic spontaneous urticaria without 
wheals, allergic angioedema), and idiopathic 
angioedema.40,41 Basic laboratory profile can 
distinguish between the two types of HAE and mast 
cell-mediated angioedema (table 1).  
Although symptoms and basic laboratory 
investigations of AAE-C1-INH  are similar to those 
of HAE-type I,  but it occurs at later age, commonly 
associated with an underlying disease such as 
lymphoma, and often depressed C1q, and negative 
family history.  Mast cell-mediated angioedema is 
frequently associated with intensely pruritic wheal 
and flare skin reactions, however, some patients 
with chronic spontaneous urticaria   do not show 
wheals and exclusively develop angioedema.42 
Because mast cell-mediated angioedema is far 
more common than HAE type I/II, on demand 
therapy with antihistamines and, if necessary, with 
epinephrine and corticosteroids, is indicated when 
the diagnosis is not yet determined, and the history 
seems to be inconsistent with HAE.43 
 
Table 1. Basic complement laboratory profile 
among patients with HAE-type I and type II and 









HAE-type I Low Low Low 







Normal Normal Normal 




The aim of management of HAE is to prevent the 
life-threatening and disabling consequences of HAE 
attacks and to normalize the patients’ activities and 
lifestyle whenever possible. Dosage and mode of 
administration of drugs used in management of 
HAE in pediatrics are summarized in table 2.  
Epinephrine, corticosteroids, and antihistamines are 
not efficacious and not recommended for the 
treatment of HAE.1,7 
 
A- Pharmacological therapy 
I- On demand-treatment: 
All of the consequences of HAE attacks can be 
minimized by using on-demand treatment. 
Laryngeal attacks should be considered as medical 
emergencies. Rapid treatment with an effective 
HAE acute medication is essential in addition to 
preparing for emergency airway management 
procedures if respiratory compromise develops.1 
During abdominal attacks, intravenous fluid 
replacement may be required because of the 
increased susceptibility of children to hypovolemia 
and dehydration, since extravasation into the 
peritoneal cavity and the intestinal lumen can be 
substantial.7 
Drugs used in acute attacks include C1-INH 
concentrate whether plasma-derived or 
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recombinant, Kallikrein inhibitor (ecallantide) and 
bradykinin-receptor antagonist (icatibant). Berinert, 
a plasma-derived C1-INH concentrate (pdC1-INH), 
is the only FDA-approved drug to be used in all 
pediatric age groups . However, recombinant C1-
INH concentrate, ecallantide and icatibant are 
recently licensed in some countries for on demand 
treatment of HAE in older children and 
adolescents.38, 44,45 
Treatment with pdC1-INH concentrate is 
effective, well tolerated and shows a good safety 
profile in pediatric patients. When pdC1-INH 
concentrate is not available,  solvent detergent-
treated plasma (SDP) is preferred over fresh frozen 
plasma (FFP), but both are considered second-line 
treatment.1,7,38 
Antifibrinolytics (e.g. tranexamic acid) or 
androgens (e.g. danazol) are not recommended for 
on-demand treatment of HAE attacks, as these 
drugs show no or only minimal effects when used 
for on-demand treatment.46   
a-C1-INH concentrate: 
Treatment results in an increase of the plasma 
levels of C1-INH and therefore helps to  inhibit the 
cascade system involved in the production of 
bradykinin during attacks. One unit of C1-INH 
concentrate corresponds to the mean quantity of 
C1-INH present in 1 mL fresh normal plasma.47,48 
 
Plasma-derived C1-INH concentrate: 
Two pdC1-INH concentrate  are available for on-
demand treatment of HAE-type I/II; Berinert  and 
Cinryze.  The mean plasma half-life of pdC1-INH 
is longer than 30 hours.49,50 The safety and 
tolerability of pdC1-INH are good, and risk of 
allergic reactions is negligible. Modern pdC1-INH 
use has not been associated with transmission of 
hepatitis B nor C nor human immunodeficiency 
viruses.51,52  Cinryze is approved  in Europe for ages 
of 12 years and older by the EMA but not FDA 
approved for on demand treatment of HAE 
attacks.38  
 
Recombinant C1-INH concentrate:  
Ruconest  is the only available recombinant human 
C1-INH (rhC1-INH). The mode of action is 
identical to that of pdC1-INH. It is derived from the 
milk of transgenic rabbits  and its  plasma half-life 
is approximately 3 hours. It is contraindicated in 
patients with known or suspected allergy to rabbits 
or rabbit derived products.53 It is both FDA and 
EMA  approved for  on demand treatment of the 
patients aged 13 and older.54 rhC1-INH has a 
favorable safety profile. Transmission of human 
viruses is not a concern.55 
b- Kallikrein inhibitor:  
Ecallantide is a 60-amino acid recombinant protein 
and has a plasma half-life of 2 hours. It inhibits 
kallikrein  and therefore, inhibits the cleavage of 
high-molecular weight kininogen to bradykinin as 
well as the further activation of FXIIa, preventing 
additional kallikrein production. Ecallantide is FDA 
approved for on demand treatment of patients 12 
years and older but not EMA approved.56 
Potentially serious hypersensitivity reactions 
including anaphylaxis,  but no deaths  have been 
reported.56, 57 
 
c- Bradykinin-receptor antagonist: 
Icatibant is a specific and selective competitive 
antagonist of the bradykinin B2 receptor and 
prevents binding of bradykinin to its receptor.  It is 
a 10-amino acid synthetic peptide and has a plasma 
half-life of 1 to 2 hours.  Icatibant is FDA and EMA 
approved for on demand treatment of patients 18 
years and older but clinical trials are ongoing in 
pediatrics.58 The safety and tolerability of icatibant 
are good, although transient local injection site 
reactions (erythema, wheal, pruritus, and burning 
sensation) can occur.59 
 
II- Pre-procedural (short-term) prophylaxis: 
Surgical trauma, dental surgery and other 
interventions associated with mechanical impact to 
the upper aerodigestive tract (e.g. endotracheal 
intubation, bronchoscopy or esophago-
gastroduodenoscopy) may lead to swellings  near 
the site of intervention. Swellings usually occur 
within 48 hours. Preprocedural prophylaxis is 
recommended for all medical, surgical and dental 
procedures associated with any mechanical impact 
to the upper aerodigestive tract.1,7 
The drugs recommended for short-term 
prophylaxis include pdC1-INH concentrate as first 
choice and short course of attenuated androgen as a 
second line. Antifibrinolytics are not recommended 
for preprocedural prophylaxis. With all pre-
procedural prophylactic treatments, break-through 
attacks can occur, so patients should remain under 
observation, and on demand treatment needs to be 
available.60-62 
 
a-Plasma-derived C1-INH concentrate: 
pdC1-INH concentrate is the first-line pre-
procedural option, the timing of administration 
varies from during procedure or one or more hours 
before the procedure but  trying to give as close to 
the procedure as possible.38 In case pdC1-INH 
concentrate is not available,  10 mL/kg  of  SDP or 
FFP can be used as a second line agent several 
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hours up to 12 hours before the expected procedure. 
However, FFP is not as safe as pdC1-INH 
concentrate  because of the greater risk of blood 
borne disease transmission, and allosensitization.34 
 
b-17α-alkylated androgens: 
The mechanisms underlying the efficacy of 
attenuated androgens are uncertain. Although 
androgens have been reported to result in a small 
increase in C1-INHmRNA levels in blood 
monocytes,63 no evidence of androgen-stimulated 
C1INH protein synthesis has been reported. 
Androgens have also been shown to increase levels 
of kininases that degrade bradykinin, which might 
contribute to their effectiveness.64 
Use of short courses of attenuated androgens 
(e.g. danazol) can be used as second line when 
pdC1-INH concentrate is not available. For 
scheduled pre-procedural prophylaxis, androgens 
can be used with mean dose suggestion of 5 
mg/kg/day (2.5-10 mg/kg/day with a maximum  of 
600 mg daily)  for 5 days before and 2 to 3 days 
post event. Very frequent short course of attenuated 
androgens may lead to side effects associated with 
long-term use.7,38 
 
III- Long-term prophylaxis: 
The aim of long-term prophylaxis (LTP) of HAE is 
to reduce the burden of the disease by 
preventing/attenuating attacks in patients with 
confirmed HAE-type I/II by using regular 
medication. However, not every patient with HAE-
type I/II should receive LTP, this should be 
individualized, and LTP should be considered in all 
severely symptomatic patients taking into 
consideration the frequency and severity of attacks, 
patient’s quality of life, availability of health-care 
resources,  failure to achieve adequate control by 
appropriate on-demand therapy and patient’s 
compliance. The pattern of HAE type I/II  attacks 
can vary over time in the same patient, therefore, 
patients should be evaluated for the need of LTP at 
every visit, at least once a year.1,7,38  
Patients who are receiving LTP should be 
evaluated  regularly for efficacy and safety of the 
therapy, and dosage and/or treatment interval 
should be adapted according to the clinical response 
rather than the C1-INH plasma level or the C4 
level.  In general, there is no need to measure C1-
INH or C4 levels in a patient with HAE once the 
diagnosis has been made.1,38 Upper airway edema 
and other attacks may occur despite the use of long-
term prophylaxis. Therefore, all patients using long-
term prophylaxis should also have on-demand 
medication.1,7,34,38 
a- Plasma-derived C1-INH 
pdC1-INH   concentrate is currently the preferred 
LTP prophylaxis for the prevention of HAE attacks. 
A dose of 10 to 20 units per kg per dose once or 
twice weekly with an initial maximum dose of 1000 
units is recommended.38 Recent study in adults 
shows that subcutaneous twice-weekly 
administration of pdC1-INH at doses of 40 U per 
kilogram or 60 U per kilogram bodyweight 
provided very good and dose-dependent preventive 
effects on the occurrence of HAE attacks.65 The 
subcutaneous route may provide more convenient 
administration as well as maintain improved steady-
state plasma concentrations of C1-INH compared to 
IV C1-INH prophylaxis. Routine prophylaxis with 
pdC1-INH has been shown to be safe and 
effective.66,67 Tachyphylaxis seems rare with only 
one report of increasing doses required to prevent 
attacks when C1-INH concentrate is used regularly 
for prophylaxis.68 Thromboembolic events due to 
pdC1-INH concentrate use in HAE are rare, and 
patients who experience such events often have 
underlying thromboembolic  risk factors.69 
 
b- Antifibrinolytics 
Antifibrinolytics (i.e. Tranexamic acid 20–50 
mg/kg/day divided in 2-3 doses with dose 
adjustment in renal impairment) are preferred to 
androgens for LTP in case pdC1-INH concentrate is 
not available  because of their better safety profile.38 
However, efficacy is questioned by many, and data 
are not available supporting its use. The mechanism 
underlying antifibrinolytic agents in the treatment 
of HAE is unknown. Epsilon aminocaproic acid is 
less well tolerated than tranexamic acid. Side 
effects are usually minor and  include 
gastrointestinal upsets (can be reduced by taking the 
drug with food), myalgia/creatine kinase elevation, 
and a theoretical risk of thrombosis. 
Contraindications include the presence of 
thrombophilia or increased thrombotic risk or acute 
thrombosis.34, 38, 70 
 
c- 17α-alkylated androgens 
Attenuated androgens are not recommended for 
LTP  in children and adolescents prior to Tanner 
stage V, however, long-term use has been reported, 
and in some cases, the benefits may outweigh the 
risks. Initial danazol dose for children is 2.5 mg/kg 
per day with subsequent adjustment, until symptom 
suppression or the maximum tolerated or maximum 
single dose of 200 mg per day  is reached. It is 
critical that the dosage be adjusted to the lowest 
dose that provides effective control of HAE. 
Because the beneficial effects of androgens occur 
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slowly, it is generally not recommended to change 
the dosage faster than once every 2 weeks.1, 15 
Androgens result in masculinization and 
hypogonadism in boys and menstruation 
irregularities in girls. Unfavourable effects on 
behaviour are possible. Reduction in ultimate body 
height may occur owing to the premature closure of 
epiphyseal growth plates.15, 34, 70  
In addition to clinical evaluation of the patient, 
semiannual blood and urine tests (standard urine 
test strip) are needed, and at least once a year, an 
ultrasound of the liver should be performed, and to 
be seen by endocrinologist at each visit.7, 15 It is 
unclear if stopping long term prophylaxis with 
attenuated androgens should be done by tapering 
off gradually over time.71 
 
B-Non-pharmacological therapy:  
Avoidance of triggers 
Infections and mechanical trauma seem to be more 
common trigger factors during childhood. 
Compulsory and recommended vaccinations for 
children are safe and the prevention of infections 
may reduce the frequency of attacks (i.e. throat 
infections). Medicinal products (ACE-I) which can 
cause edema as an adverse effect should be avoided 
although are less frequently used in pediatrics. 
Other triggers like strenuous physical activities 
involving mechanical trauma and emotional 
challenges (stress) are essential elements of 
childhood and adolescence and should be decreased 
whenever possible.1, 7, 15, 72 
 
Patients and family education 
Providing appropriate education to pediatric 
patients and their families is indispensable to 
support them to have a suitable lifestyle and to 
avoid complications. Teachers, and health care 
personnel responsible for the child at daycare or 
school should receive written information on the 
disease, with advice on management of HAE 
attacks, including the urgency of treatment for 
airway attacks. Pediatric patients should have an 
information card containing a description of 
emergency procedures including on demand 
treatment for emergency use. Alert devices, 
including identifying wrist or neck bands with 
emergency contact information, should also be 
considered. The pdC1-INH concentrate for 
emergency use should be available at home, 
however, it is extremely important to encourage all 
patients to seek further care immediately after 
administration of therapy to reduce the risk of 
potentially fatal complications as in upper airway 
swelling. 7, 38, 40, 73 
Home therapy and self-/assisted administration 
Based on the experience with hemophilia where 
children are benefited by taking an active part early 
in their treatment, and even at the age of 8, IV self-
administration has been proven possible and safe, 
C1-INH concentrate home therapy is also suitable 
for children with frequent or disruptive attacks. 
Therefore, self-or assisted treatment techniques 
should be discussed, and training programs should 
be offered to parents and pediatric patients.40,74 
Other considerations 
All patients should be screened for hepatitis B and 
C and HIV. Vaccinations for hepatitis A and B are 
recommended by many experts. All patients should 
be considered to receive influenza vaccine and 
other routine vaccinations.38 
Patient organizations and support groups provide 
help and support for HAE patients, caregivers, and 
family members. They endorse the philosophy that 
all patients worldwide should have sufficient 
resources to control their HAE symptoms and fulfil 
their potential at school, at work, and in their 
relationships. Patient organizations also work 
toward identifying and addressing unmet needs in 
HAE management, which include the development 
of safe and well tolerated new prophylactic and on-
demand therapies, the optimization of existing long-
term prophylactic and on-demand therapies, 
increasing the availability of modern treatment 
options worldwide, emphasizing the need for self-
care, individual action plans, early therapy, and 
gene therapy research. HAEi is the international 
umbrella organization for the world’s Hereditary 
Angioedema (HAE) patient groups, provide  active 
informative web sites for patients and health care 
providers.7   
 
Burden of HAE 
It is impossible to predict the ultimate severity of an 
attack at the onset of that attack. Swelling of the 
extremities can result in temporary inability to walk 
because of swelling of the feet or to use the swollen 
hand for writing or typing. Subcutaneous swelling 
is a common cause of school absenteeism and may 
affect a child’s progress in school and participation 
in sports and other daily activities.20,22 
Genitourinary attacks can cause significant 
discomfort and lead to a temporary inability to 
urinate. Abdominal attacks are a frequent cause of 
morbidity. The angioedema can result in severe 
abdominal pain with intractable nausea and 
vomiting and third-space sequestration of fluid that 
can induce significant hypotension.7 Moreover, 
many patients with HAE may undergo unnecessary 
and inappropriate surgical interventions because of 
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severe abdominal attacks. Angioedema of the 
oropharynx in patients with HAE is capable of 
suffocation and resulting in death.1 The cost of the 
disease in developing countries without specific 
medications for C1-INH-HAE is often excessive 
absenteeism, significant morbidity, failure to 
maintain employment, and higher risk of 
mortality.75, 76  
 
 
Table 2. Doses, mode of administration and indication of drugs used in management of HAE-type I/II 
Drug category  
(trade name) 




Plasma derived C1-INH 
concentrate (Berinert) 
10-20 Units /kg with a 
maximum initial dose of 
1000 units-intravenous 
On-demand treatment/ 
STP and LTP 
Hypersensitivity reactions-
theoretical risk of transmission 
of blood borne infections 
Plasma derived C1-INH 
concentrate (Cinryze) 
10-20 Units /kg -
intravenous 
1000 units once or twice 
weekly (LTP) 
Children 12 years and 




theoretical risk of transmission 
of blood borne infections 
Recombinant C1-INH 
(Ruconest) 
50 unit /kg -intravenous On-demand treatment 
in children 13 years 
and older 
Hypersensitivity reactions in 
patients with allergy to the 
rabbit and its products 
Kallikrein inhibitor-Ecallantide 
(Kalbitor) 
30 mg subcutaneous On demand treatment 
in children 13 years 
and older 
Risk of anaphylaxis, needs 
medical supervision. 
17 α-alkylated androgens 
(Danazol) 
Oral-2.5-10 mg/kg/day 
(average 5 mg/kg/day) 
STP: maximum 600 mg 
daily 
LTP: maximum 200 mg 
daily better to titrated to 
EOD 
Second line agent in 
prophylaxis in patients 




Weight gain, elevation of the 
liver enzymes, menstrual 
irregularities and negative 
effect on the height 
Antifibrinolytics/Tranxamic 
acid (Cyklocapron) 
20-50 mg /kg /day 
maximum 3-6 gm daily 
LTP GIT upset, 
increased risk of thrombosis 
(uncommon) 
C1-INH: C1-esterase inhibitor; STP: short-term prophylaxis; LTP: long term prophylaxis; GIT: gastrointestinal; EOD: every other day 
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